Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Various PD-1 and PD-L1 checkpoint inhibitors have been approved by U.S. regulators including blockbuster drugs Keytruda, Imfinzi, and Opdivo to treat different types of cancer. But that hasn’t stopped ...

First-in-class drugs are therapies that utilize novel mechanisms of action, offering new approaches to challenging diseases. In 2024, the U.S. Food and Drug Administration (FDA) approved 50 new ...

As the industry plunged into the holiday season in December, the last month of the year saw fewer merger and acquisition (M&A) deals compared to November. AbbVie took the top spot with its acquisition ...